Amerikanische Gesellschaft für Hirudotherapie

Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour

Research article published in Biomedica biochimica acta (1990)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryArzneimittelentwicklungMarkwardt F et al. · Biomedica biochimica acta, 1990

Abstract

Recombinant desulphatohirudin was bound via lysine residues to oxidized dextrans. The hirudin-dextran conjugates inhibit thrombin like free hirudin. The Ki-values are in the same range. In rabbits and rats the pharmacokinetic behaviour following i.v. administration of these conjugates was examined in comparison to that of hirudin. The hirudin-dextran conjugates were more slowly eliminated than hirudin, the distribution volumes in steady-state were significantly reduced, and, in comparison to hirudin, 5 to 15 times larger areas under the plasma concentration-time-curves were obtained.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsAnimalsChromatography, High Pressure LiquidDextransFibrinolytic AgentsHirudinsMolecular WeightPharmacokineticsRabbitsRatsRats, Inbred StrainsRecombinant Proteins

Zusammenfassung

Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour.

Warum dies für die Hirudotherapie relevant ist

This study examined recombinant desulphatohirudin chemically conjugated to oxidized dextrans via lysine residues and its pharmacokinetic behavior after intravenous administration in rabbits and rats. The conjugates inhibited thrombin with Ki-values in the same range as free hirudin, while showing slower elimination, significantly reduced steady-state distribution volumes, and 5- to 15-fold larger areas under the plasma concentration-time curves compared with unconjugated hirudin. For ASH's domain, the relevance is indirect: hirudin is the potent thrombin inhibitor originally characterized from the medicinal leech, and the work illustrates a formulation strategy for prolonging its circulatory exposure. However, the compound studied is recombinant desulphatohirudin bound to dextran rather than a native leech-secretome component, the study is limited to animal pharmacokinetics, and no therapeutic efficacy or safety data are provided.

Zitation

Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour

Markwardt F et al. · Biomedica biochimica acta, 1990

DOIPubMed

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsHirudinAnticoagulation CompoundsHemostasisOtolaryngology

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.